

1

2 **Intramyocardial cell-based therapy during bidirectional cavopulmonary anastomosis for**
3 **hypoplastic left heart syndrome: The ELPIS phase I trial**

4

5 Brief title: *Phase I ELPIS trial*

6

7 Sunjay Kaushal, MD, PhD^a, Jessica R Hoffman, BS^b, Riley M Boyd, BA^a, Joshua M Hare, MD^{c,d},
8 Kevin N. Ramdas, MD, MPH^c, Nicholas Pietris, MD^e, Shelby Kutty, MD, PhD, MS^f, James S
9 Tweddell, MD^g, S. Adil Husain, MD^h, Shaji C. Menon, MBBS, MD, MSⁱ, Linda M. Lambert,
10 MSN-cFNP^j, David A Danford, MD^k, Seth J Kligerman, MD^l, Narutoshi Hibino, MD, PhD^m,
11 Laxminarayana Korutla, PhDⁿ, Prashanth Vallabhajosyula, MD, MSⁿ, Michael J. Campbell, MD^o,
12 Aisha Khan, PhD^d, Keyvan Yousefi, PharmD, PhD^c, Danial Mehranfard, PharmD, MBA^c, Lisa
13 McClain-Moss^c, Anthony A. Oliva, PhD^c, Michael E Davis, PhD^b

14

15 **Affiliations:**

16 a) Division of Cardiovascular-Thoracic Surgery, Ann & Robert H. Lurie Children's Hospital of
17 Chicago, Department of Surgery (Cardiac) and Department of Pediatrics, Northwestern
18 University Feinberg School of Medicine, Chicago, IL

19 b) Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology
20 & Emory University School of Medicine, Atlanta, GA

21 c) Longeveron Inc, Miami, FL

22 d) Department of Medicine and Interdisciplinary Stem Cell Institute, University of Miami Miller
23 School of Medicine, Miami, FL

- 1 e) Division of Pediatric Cardiology, Department of Pediatrics, University of Maryland School of
2 Medicine, Baltimore, MD
- 3 f) Helen B. Taussig Heart Center, The Johns Hopkins Hospital and Johns Hopkins University,
4 Baltimore MD
- 5 g) Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
- 6 h) Division of Pediatric Cardiothoracic Surgery, University of Utah/Primary Children's Medical
7 Center, Salt Lake City, UT
- 8 i) Department of Radiology, University of Utah/Primary Children's Medical Center, Salt Lake
9 City, UT
- 10 j) Division of Pediatric Cardiology, University of Utah/Primary Children's Medical Center, Salt
11 Lake City, UT
- 12 k) Division of Cardiology, Children's Hospital & Medical Center, Nebraska Medicine,
13 Department of Pediatrics, University of Nebraska, Omaha, NE
- 14 l) Department of Radiology, University of California San Diego, San Diego, CA
- 15 m) Department of Surgery, The University of Chicago Medical Center, Chicago, IL
- 16 n) Department of Surgery (Cardiac), Yale School of Medicine, Yale University, New Haven, CT
- 17 o) Department of Pediatrics, Duke University School of Medicine, Durham, NC

18

19 **SOURCES OF FUNDING:** The ELPIS trial is funded through the Maryland Stem Cell Research
20 Fund (MSCRF) grant #2017-MSCRFCL-3955, Children's Heart Foundation. S.K. is funded by
21 grants from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute
22 (R01HL118491, R01 HL139060-01A1, R42HL131226-01); and Moseley Foundation. J.M.H. is
23 funded by grants from the NIH/National Heart, Lung, and Blood Institute (R01 HL107110,

1 1R01HL134558-01, 4R01HL084275-10, 5R01HL116899-04, and HHSN268201600012D);
2 NIH/National Cancer Institute (5R01CA136387-07); Soffer Foundation; Marcus Foundation, and
3 Starr Foundation. M.S. is funded by NIH grant K08HL146351. A.A.O. is funded by grants from
4 the National Institutes of Health (NIH)/National Institute on Aging, the MSCRF, and Alzheimer's
5 Association. M.E.D. is funded by grants from the NIH/National Heart, Lung, and Blood Institute
6 (R01HL145644) and through the Marcus Foundation.

7
8 **DISCLOSURES:** J.M.H. is a stockholder in Vestion, Inc., Heart Genomics, and Longeveron,
9 Inc. J.M.H. is the Chief Scientific Officer, a compensated consultant and board member for
10 Longeveron, and holds equity in Longeveron. J.M.H. is also the co-inventor of intellectual
11 property licensed to Longeveron. Dr. Hare's relationships are disclosed to the University of
12 Miami, and a management plan is in place. S.K. is a founder of Neoprogen, Inc. The University
13 of Miami is an equity owner in Longeveron, which has licensed intellectual property from the
14 University of Miami. KNR, KY, DM, LM, and AAO are full-time employees of Longeveron Inc.

15
16 **Address for Correspondence:**

17 Sunjay Kaushal MD, PhD
18 Division of Cardiovascular-Thoracic Surgery,
19 Ann & Robert H. Lurie Children's Hospital of Chicago,
20 225 E. Chicago Ave, Chicago, Illinois, 60611
21 Phone: (312) 227-4240; Fax: (312) 227-9643
22 skaushal@luriechildrens.org

23

1 **ABSTRACT**

2 **Background:** Hypoplastic left heart syndrome (HLHS) survival relies on surgical reconstruction
3 for the right ventricle (RV) to provide systemic circulation. This leads to substantially increased
4 loads on the RV, wall stress, maladaptive remodeling and dysfunction, which in turn can increase
5 risk of death or transplantation.

6 **Objectives:** We conducted a phase I multicenter trial to assess safety and feasibility of intra-
7 operative MSC injection in HLHS patients to boost RV performance in the systemic position.

8 **Methods:** Allogeneic MSCs were directly administered by intramyocardial injections during the
9 second stage palliative operation. The primary endpoint was safety.

10 **Results:** Ten patients received intramyocardial injections of allogeneic MSCs (Lomecel-B). No
11 patients experienced major adverse cardiac events (MACE). All subjects were alive and
12 transplant-free at 1 year following, and experienced growth comparable to healthy control
13 historical data. Cardiac magnetic resonance imaging (CMR) revealed improving tricuspid
14 regurgitant fraction (Baseline: 0.45 ± 0.19 ; 6 mo.: 0.32 ± 0.06 ; 12 mo.: 0.06 ± 0.09), while global
15 longitudinal strain (Baseline: -24.39 ± 6.99 ; 6 mo.: -20.55 ± 3.05 , $p > 0.05$ vs baseline; 12 mo.: -
16 23.88 ± 4.6 , $p > 0.05$ vs baseline) and RV ejection fraction (EF; baseline: 62.62 ± 5.99 ; 6 mo.:
17 53.69 ± 9.56 ; 12 mo.: 52.31 ± 5.63 ; $p = NS$ for change over time) were unchanged. Computational
18 modeling identified 167 derived RNAs specific to circulating exosomes originating from
19 transplanted MSCs corresponding to RVEF changes and identifying potential mechanistic
20 underpinnings.

21 **Conclusions:** Intramyocardial MSCs appear safe in HLHS patients, and may favorably affect RV
22 performance. Circulating exosomes of transplanted MSC-specific provide novel insight into
23 bioactivity. Conduct of a controlled phase trial is warranted and is underway.

1

2 **Key Words**

3 Lomcel-B; allogeneic medicinal signaling cells; mesenchymal stem cells; mesenchymal stromal
4 cells; Hypoplastic left heart syndrome; HLHS

5

6 **Condensed Abstract**

7 The ELPIS phase I trial was designed to assess safety and feasibility of intramyocardial injection
8 of allogeneic MSCs into the RV during second stage palliation of HLHS. There were no
9 incidences of major adverse cardiac events (MACE) or other safety concerns, and there was a
10 100% transplant-free survival at 1-year follow-up, supporting the safety and feasibility of this
11 approach. The ELPIS results are important for advancing MSC therapy for all ages and
12 congenital heart conditions, and warrant further investigation in a controlled Phase II trial
13 powered for efficacy.

1 **ABBREVIATIONS:**

2	BDCPA	bidirectional cavopulmonary anastomosis
3	BNP	brain natriuretic peptide
4	BSA	body surface area
5	CMR	cardiac magnetic resonance imaging
6	Phase 1 ELPIS Trial	Allogeneic Human Mesenchymal Stem Cell Injection in Patients with
7		Hypoplastic Left Heart Syndrome: An Open Label Pilot Study
8	GLS	global longitudinal strain
9	HLHS	hypoplastic left heart syndrome
10	HAS	human serum albumin
11	HIV	human immunodeficiency virus
12	MACE	major adverse cardiac events
13	MSCs	medicinal signaling cells
14	PCA	principal component analysis
15	PLSR	partial least squares regression
16	RNA	ribonucleic acid
17	RV	right ventricle/right ventricular
18	RVDd	right ventricular end-diastolic diameter
19	RVDs	right ventricular end-systolic diameter
20	RVEDV	right ventricular end diastolic volume
21	RVEF	right ventricular ejection fraction
22	RVESV	right ventricular end systolic volume
23	RVSV	right ventricular stroke volume

- 1 TOM topological overlap matrix
- 2 TR tricuspid regurgitation
- 3 TR RF tricuspid regurgitant fraction
- 4 WGCNA weighted gene co-expression network analysis

1 INTRODUCTION

2 Hypoplastic left heart syndrome (HLHS) is one of the most severe and complex congenital heart
3 defects that inevitably leads to death without intervention (1). With an incidence of approximately
4 2-3.5 per 10,000 live births (2-4), children with HLHS have an underdeveloped left ventricle that
5 is unable to support the systemic circulation, along with hypoplasia of the ascending aorta and
6 stenosis or atresia of the mitral and aortic valves (5). HLHS is no longer a fatal diagnosis because
7 of the development of surgical palliation through 3-staged surgical operations (6-8). Nevertheless,
8 HLHS has a high mortality of up to 36.5%, especially during the interstage period throughout the
9 first year of life (9). This is due, at least in part, to the significant mechanical loads imposed upon
10 the RV causing stress on the right ventricle (RV) that now must support systemic circulation.
11 Increased load can lead to RV hypertrophy and dysfunction, and often requires heart
12 transplantation due to RV failure. However, transplantation is limited by organ availability,
13 limited organ lifespan, and less beneficial outcomes in patient with HLHS when compared with
14 other indications (10).

15 The unique challenges posed by HLHS have necessitated the pursuit of novel therapies to
16 improve outcomes for the single-ventricle population. Cell-based therapy has the potential to
17 safely improve myocardial function and reverse maladaptive remodeling following injury (11-14).
18 Moreover, such approaches have shown promise in treating various adult cardiac conditions (12,
19 13, 15-17), and along with preclinical animal studies modeling RV pressure overload (18), and
20 acute ischemic injuries (19), provide strong rationale for the application to HLHS. There are few
21 studies investigating the use of cell-based therapies in patients with HLHS (20-25), and none to
22 date have studied the use of MSCs. Autologous cell-based therapies carry the benefits of avoiding
23 immune therapies; however, have a number of drawbacks, including logistic and economic

1 constraints, feasibility failures for manufacturing, and often undiagnosed medical comorbidities
2 and potential genetic disease contributors. In contrast, allogeneic MSCs circumvent these issues
3 and have shown potential promise over autologous MSCs in the POSEIDON trial for dilated
4 cardiomyopathy patients (26). Preclinical and clinical studies have demonstrated that allogeneic
5 MSCs are immunoprivileged, and thus tissue-type matching and immunosuppressive therapy are
6 not needed (26). Since the MSCs can be administered by direct intramyocardial injection, this
7 obviates the need for traversing the endothelial barrier such as would be required with
8 intracoronary administration.

9 Here we present the results of the phase I ELPIS trial. The primary objective was to
10 demonstrate the safety and feasibility of intramyocardial injection of MSCs during the Stage II
11 bidirectional cavopulmonary anastomosis (BDCPA) surgery (27). To address limitations to
12 noninvasively monitor transplanted cells in a repeatable, time-sensitive manner, we assayed
13 circulating exosomes of transplanted MSCs and used computational modeling to evaluate the
14 bioactivity and dynamics of the transplanted cells.

15

16 **METHODS**

17 This study was under the oversight of an independent Institutional Review Board (Western IRB:
18 Puyallup, WA) and Data Safety Monitoring Board (DSMB). The consent form, protocol, and all
19 supporting documents were also reviewed by the IRBs of participating centers: University
20 Maryland Medical Center, Cincinnati Children's Hospital Medical Center, and Primary Children's
21 Medical Center. Methods were previously reported. (27), and briefly described as follows.

22 **Study Design and Patient Population**

1 The patients in this report were enrolled under two studies: a formal phase I safety study using an
2 allogeneic MSC formulation called Lomecel-B (Longeveron Inc.: Miami, FL. $N=10$;
3 NCT03525418); and a second set of 4 patients enrolled in a run-in using allogeneic MSCs
4 produced by the Interdisciplinary Stem Cell Institute (University of Miami Miller School of
5 Medicine: Miami, FL. $N=4$; NCT02398604). The aims were to assess: 1) the safety and
6 feasibility of intramyocardial allogeneic MSC injection in patients with HLHS during stage II
7 palliation; 2) provisional, hypothesis generating phenotypic data to design future phase II studies,
8 and 3) novel exosome/microRNA biomarker information to gain mechanistic insights. Patients
9 fulfilling inclusion and exclusion criteria were offered enrollment in the studies, and similar
10 inclusion and exclusion criteria were used for both protocols. Inclusion criteria required enrolled
11 patients to have any type of HLHS requiring BDCPA surgery. Exclusion criteria included: having
12 HLHS and a severely restrictive or intact atrial septum; patients undergoing the Norwood
13 procedure who do not have HLHS; presence of significant coronary artery sinusoids; patients
14 requiring mechanical circulatory support before surgery; evidence of arrhythmia requiring
15 antiarrhythmic treatment prior to enrollment; unwillingness or inability of parent(s) or guardian(s)
16 to comply with necessary follow-up(s); patients who are serum positive for HIV, hepatitis B
17 surface antigen, or viremic hepatitis C; or who are unsuitable for inclusion in the study as
18 determined by the investigator. Parents or guardians provided written consent before enrollment
19 (Figure 1A). Enrolled patients then received baseline cardiac magnetic resonance imaging (CMR)
20 before the stage II operation. At Stage II palliation, patients received intramyocardial injections of
21 allogeneic MSCs and received follow-ups at 6- and 12-months after surgery (Figure 1A).

22

23 **Cell Harvesting and Intramyocardial Injection**

1 Cells were produced using current Good Manufacturing Practices (12, 28) at Longeveron, Inc.,
2 Miami, FL (N=10; NCT03525418; Lomecel-B) and the University of Miami Interdisciplinary
3 Stem Cell Institute (N=4; NCT02398604). The trials were conducted under two unique
4 Investigational New Drug applications from the U.S. Food and Drug Administration. Cell
5 harvesting, processing, and manufacturing were performed similar to as previously described (27).
6 Release criteria for the MSCs met minimal release criteria of >70% viability, negative Gram
7 staining, low levels of endotoxin, sterility, and being >95% CD105⁺ and CD90⁺ cells, consistent
8 with previous trials (12, 28).

9 The allogeneic MSCs were delivered as previously described, and an RV map of the 8
10 injection sites in the RV free wall has been previously published (27). Target cell doses of $2.5 \times$
11 10^5 cells/kg were used, actual doses based on weight in the formal phase I trial were between 1-2
12 $\times 10^6$ cells administered in 600 μ L. The entire dose was divided and delivered in 4 intramyocardial
13 injections of 100 μ L and 4 intramyocardial injections of 50 μ L per injection (27). The remainder
14 of the BDCPA operation proceeded as anticipated. This was similar to the methods for
15 intramyocardial administration and dosing of allogeneic MSCs used in the PROMETHEUS (28)
16 and POSEIDON (12) trials.

17

18 **Study Endpoints**

19 The primary objective of the phase I ELPIS trial was safety, with the primary endpoint being the
20 incidence of MACE (defined as sustained/symptomatic ventricular tachycardia requiring inotropic
21 support, aggravation of heart failure, myocardial infarction, unplanned cardiovascular operation
22 for cardiac tamponade, or death) one-year post-BDCPA or infection within one month of
23 treatment. The safety data was reviewed three times during the course of the trial and a final formal

1 study report analysis was conducted by the independent DSMB. The DSMB did not report any
2 concerns with safety or feasibility, and recommended advancement to the next phase.

3 Secondary endpoints included functional cardiac changes from baseline, change in somatic
4 growth, and assessment of comorbidities. Cardiac function measurements included RV ejection
5 fraction (RVEF), body surface area (BSA)-indexed RV stroke volume (RVSV), RV end-diastolic
6 volume (RVEDV), RV end-systolic volume (RVESV), BSA-indexed RV end-diastolic diameter
7 (RVDD), BSA-indexed RV end-systolic diameter (RVDs), RV global longitudinal strain (GLS),
8 and qualitative tricuspid regurgitation (TR) and TR fraction (TR RF) measured by serial
9 echocardiograms and CMR. Other secondary endpoints were need for transplantation, re-
10 hospitalizations, cardiovascular mortality, and all-cause mortality.

11

12 **Exosome analyses**

13 An exploratory sub-study was performed in 6 of the 14 patients in which exosome RNA expression
14 was determined with Human Clariom S Assay and GeneChip miRNA 4.0 Arrays (Applied
15 Biosystems), and correlated with functional outcomes. Exosomal miRNA was measured from 6
16 patients, and exosomal total RNA was profiled in 6 patients. Data were processed and annotated
17 with the following R packages: oligo (29), pd.clariom.s.human (30),
18 clariomshumantranscriptcluster.db (31), miRBaseVersions.db (32), and pd.mirna.4.0. (33) Lowly
19 expressed RNAs and multiple mappings were removed. Then, data were quantile normalized with
20 robust multi-array method. Based on plasma and CMR data availability, 6 months-to-1 year fold
21 change values for RV mass, RVEDV, RVESV, RVSV, RVEF, TR RF, and GLS from 6 patients
22 (E1, E2, E3, E4, E5, E6) were used in subsequent analyses.

23

1 **Unsupervised analysis of filtered, normalized RNA**

2 Differential expression of gene (DEG) analysis for day two and day seven patient matched
3 exosomes was performed using a paired, two-tailed Student's t-test. Results indicated similar
4 expression levels at both days (0.10% of RNAs with $p < 0.05$ and $|\text{fold change}| > 1.5$). Thus, for the
5 remaining analyses, day seven exosome RNA expression was used. Principal component analysis
6 (PCA) was performed using the SIMCA-P software (Umetrics, Sartorius Stedim Biotech).

7 The WGCNA R package was used to construct co-expression networks for the filtered,
8 normalized genes. The details of this algorithm are described by Langfelder and Horvath(31).
9 Briefly, the optimal soft-threshold power was graphically determined ($\beta = 12$ and 20 for miRNA
10 and RNA) and the minimum module size was set to 50. Clusters, or modules, of RNAs were
11 determined by first computing the adjacency matrix and then transforming it to form the
12 topological overlap matrix (TOM). Then, the corresponding dissimilarity matrix, 1-TOM, and the
13 cutree Dynamic function was used for hierarchical clustering and module detection. Highly
14 correlated modules ($r > 0.75$) were merged to form the final co-expression modules. Twenty-five
15 miRNA and RNA modules were determined, each. The dissimilarity of the module Eigengenes
16 was computed with the module Eigengenes function and the association between Eigengene values
17 and CMR outcomes were assessed by Spearman's correlation.

18

19 **Partial least squares regression (PLSR) and biological pathway analyses**

20 PLSR modeling was performed using SIMCA-P software (Umetrics, Sartorius Stedim Biotech).
21 A regression model was built from six patients' (E1, E2, E3, E4, E5, E6) day seven exosome RNA
22 signals, with 6 months-to-1 year fold change CMR values. Feature selection was performed to
23 select the top 200 RNA signals with the highest variable importance in the projection (VIP) values

1 and a final two-component model was built. miRTarBase was used to identify experimentally
2 validated miRNA gene targets (≥ 3 experiments; mirtarbase.cuhk.edu.cn). Gene Ontology and
3 KEGG pathway enrichment of genes and miRNA gene targets was determined using Metascape
4 (metascape.org). The web-based Metascape tool determined the significantly enriched terms from
5 gene sets ($p < 0.05$).

6

7 **Statistical Analyses**

8 Cardiac functional parameters, somatic growth, and brain natriuretic peptide (BNP) were
9 compared at the various timepoints. Normality of parameter distributions was evaluated using a
10 Kolmogorov-Smirnov test. For continuous measurements that were not normally distributed at all
11 timepoints, comparisons among values at the 3 timepoints were made using a Kruskal-Wallis H-
12 test followed by a Dunn's Multiple Comparison test. Normally distributed measurements were
13 compared using one-way analysis of variance (ANOVA), with correction for multiple
14 comparisons. The statistical significance threshold was $p \leq 0.05$. Statistical analyses were
15 completed using SPSS and GraphPad Prism 9.

16

17 **RESULTS**

18 **Patient and Operative Characteristics**

19 This report comprises the formal phase I ELPIS trial ($N=10$), and an additional group ($N=4$) with
20 similar characteristics enrolled as a run-in. The baseline characteristics of the patients are shown
21 in Table 1. All participants were diagnosed with HLHS, with most patients having mitral and
22 aortic atresia (61.5%). The average weight for age z-score was -0.9 for the study group. Each

1 patient had previously undergone the Stage I (Norwood) surgery with a Sano shunt at an average
2 age of 4.4 days (Table 2).

3 All patients received intramyocardial MSC injections during the BDCPA procedure. The
4 total cardiopulmonary bypass averaged 113.1 ± 17.44 minutes (Table 3). The average time for
5 allogeneic MSC injection was 5.5 ± 1.78 minutes. No patient underwent aortic cross-clamping or
6 deep hypothermic circulatory arrest. Concomitant atrial septectomy was completed in three
7 patients and concomitant pulmonary artery patch augmentation was completed in four patients;
8 the remaining patients underwent no concomitant procedures. Nine of the patients enrolled in the
9 formal phase I trial were seen at the 6-month follow-up and 8 were seen at the 12-month follow-
10 up (Figure 1B).

11

12 **Safety: Results of the formal phase I study**

13 Ten patients successfully underwent BDCPA receiving intramyocardial Lomecel-B injection
14 during the Stage II surgery. No adverse events on trial were attributed to Lomecel-B (Table 4).
15 Specifically, no treated patients had myocardial infarction, death, ventricular arrhythmia, systemic
16 infection, stroke, or allergic reaction. No myocardial ischemia was seen by monitoring
17 electrocardiogram and telemetry. Two patients experienced an infectious event within one month
18 of surgery: one urinary tract infection; and one methicillin-resistant *Staphylococcus aureus*
19 bacteremia. These events were not considered related to treatment. No mortality or heart-
20 transplantation was recorded in the one year following treatment. Ten re-hospitalizations occurred
21 in 5 patients, which were not related to worsening RV function. One subject required catheter-
22 mediated angioplasty for an ascending aortic obstruction. HLA class I reactions were decreased at

1 26 weeks post-treatment as compared to baseline ($p = 0.031$; Figure 4E). HLA class II reactions
2 showed a trend toward reduction ($p = 0.25$, Figure 4F).

3

4 **Postoperative Outcomes**

5 Cardiac function was assessed by CMR 3 times over a 1-year period after treatment. RVEF which
6 was normal at baseline ($62.62 \pm 5.99\%$) showed a non-significant trend towards reduction at 6 and
7 12 months ($53.69 \pm 9.56\%$ and $52.31 \pm 5.63\%$, respectively) (Figure 2A, Supplemental Tables 1 and
8 2). RVSV index did not significantly change from baseline to 6 months (-4.05 ± 33.35 ml, $p > 0.05$)
9 or 12 months (-12.75 ± 34.8 ml, $p > 0.05$; Figure 2B, Supplemental Table 1). RVDd and RVDs did
10 not significantly change from baseline at either 6 or 12 months ($p > 0.05$, Figure 2C, 2D,
11 Supplemental Table 1). GLS did not change from baseline to 6- or 12-months post-treatment
12 (Figure 2E, Supplemental Table 1). TR was assessed subjectively and quantitatively by CMR
13 (Figure 3A, 3B). The mean TR RF decreased from 0.45 ± 0.19 at baseline to 0.32 ± 0.06 ($p > 0.05$),
14 and to 0.06 ± 0.09 ($p > 0.05$; Figure 3B, Supplemental Table 1). The serum BNP increased
15 following day two post-treatment, decreased following week twenty-four post-treatment (Figure
16 4A) and the change in BNP from baseline was not significant ($p > 0.05$; Figure 4B). No significant
17 changes were observed in weight for age z-score at 6 months ($p = 0.30$ vs baseline) or 12 months
18 ($p = 0.73$ vs baseline; Figure 4C, Supplemental Table 1). No significant changes were observed
19 in length for age z-score at 6 months ($p = 0.079$ vs baseline) or 12 months ($p = 0.946$ vs baseline;
20 Figure 4D, Supplemental Table 1). However, the length for age z-score significantly decreased
21 from 1.24 ± 1.64 at 6-month to -0.40 ± 1.83 at 12-months ($p = 0.0136$).

22

23 **RNA expression profiles in MSC-derived exosomes**

1 We hypothesized that injected MSCs would release exosomes composed of allogeneic cell-specific
2 constituents, and that these would be detectable in the recipient blood. Using a MHC mismatch
3 technique based on the donor and recipient MHC profiles, MSC-derived exosomes (HLA-I+) were
4 collected at 2 and 7 days post-treatment from the plasma of 6 patients: 2 from the phase I safety
5 study, and 4 from the run-in (E1- E6). Immunoblot analysis demonstrated allogeneic MSC-derived
6 exosomes expressed respective HLA-I molecules, flotillin (exosome marker), and c-kit (progenitor
7 marker) (Figure 5A, Figure 6). Total RNA and miRNA in exosomes were quantified by
8 microarray, and differential expression of RNAs between time points were assessed (Figure 5B).
9 Exosomal expression profiles remained stable between days 2 and 7 with 0.1% (17 of 16,351) of
10 RNAs differing ($p < 0.05$ and $|\text{fold change}| > 1.5$). Additionally, principal component analysis
11 (PCA) of RNA and miRNA arrays do not show distinct clustering of day 2 and 7 samples (Figure
12 5C, 5D). However, there was separation of patients E2 and E3 in total RNA PCA plot.

13 CMR endpoints (RVSV, RVEDV, RVESV, RV mass, RVEF, GLS, and TR RF) were
14 collected six-months and one-year after surgery and MSC treatment from six patients: E1, E2, E3,
15 E4, E5, E6. TR RF was not collected for E5 and E6. Based on CMR and plasma availability, further
16 analyses were conducted with these patients ($N=6$), using fold change values, or improvements,
17 from six-months to one year.

18

19 **Weighted correlation network analysis (WGCNA) of day 7 exosomes**

20 WGCNA was performed with day 7 exosomal total RNA and miRNA expression values to
21 construct co-expressed networks and identify co-expression clusters, or modules. Twenty-five co-
22 expression modules were identified for both total RNA and miRNA, and their hierarchical
23 clustering is illustrated in the dendrograms (Figure 5E, 5F). Modules of highly correlated genes

1 were determined independently from CMR outcomes. Then, modules were summarized by module
2 eigengenes and related to CMR 6 months-to-1 year fold change values in the lower heatmaps.
3 Modules that significantly correlated with an outcome, negatively or positively, are marked ($p <$
4 0.1).

5 Next, we investigated the exosomal RNA modules which correlated with TR RF
6 improvement, or six-months to one-year reductions. Three miRNA modules (M12, M20, and M25)
7 positively correlated with TR RF fold change ($r < 0$, $p < 0.001$), and two total RNA modules (M1
8 and M5) negatively correlated with TR RF fold change ($r > 0$, $p < 0.001$). To determine the
9 biological significance of these modules, we first identified experimentally validated miRNA gene
10 targets, and then completed pathway analysis on the miRNA module gene targets and total RNA
11 module genes. Enriched gene ontology parent terms of the modules include immune system
12 processes, cellular processes, biological adhesion, and growth (Figure 5G). Pathway analysis of
13 the three miRNA modules' gene targets alone indicate enrichment of terms including, positive
14 regulation of cell migration, response to growth factor, VEGFA-VEGFR2 signaling, and apoptotic
15 signaling (Figure 5H).

16

17 **Partial least squares regression (PLSR) of day 7 exosomes**

18 In addition to using unsupervised WGCNA, we also conducted supervised analysis with PLSR to
19 establish a relationship between exosomal RNAs and CMR outcomes. A regression model was
20 built from six patients' (E1, E2, E3, E4, E5, E6) day seven exosome RNA signals, with 6 months-
21 to-1 year fold change CMR values. Feature selection reduced the initial list of 16,351 to the 200
22 RNA variables with the greatest importance for the model projection (VIPs). Notably, the resulting
23 feature reduction increased the proportion of miRNAs considered, indicating their importance in

1 the regression model (Figure 7A). A two-component model of these top 200 VIPs captured the
2 variance of RNA signals and CMR outcomes with high coefficients of determination: $R^2(\text{RNA}) =$
3 0.927 , $R^2(\text{CMR Outcomes}) = 0.865$. The PLSR scores plot shows the spread of patient samples
4 across the two components (Figure 7B). The PLSR loadings plot displays how the 200 VIP signals
5 covary with CMR outcomes and show two distinct clusters across component one (Figure 7C).
6 Furthermore, the top 200 RNA signals predicted CMR outcomes with high R^2 values, slopes ~ 1 ,
7 and low root mean square error of estimation (Figure 7D).

8

9 **Intersection of Unsupervised and Supervised Learning Methods - RNAs related to TR RF**

10 To determine the RNAs related to changes in TR RF, we considered the intersection of both
11 analyses, WGCNA and PLSR. We overlapped genes from the WGCNA modules which correlate
12 to TR RF fold change (miRNA modules M12, M20, M25 and total RNA modules M1 and M5)
13 and the top 200 VIPs from the PLSR module (Figure 7E). We identified 54 RNAs in the
14 intersection and determined the RNAs with the largest weighted coefficient for TR RF fold change
15 in the PLSR model (Figure 7F). Pathway analysis of these 54 RNAs indicated significant
16 enrichment of terms including, negative regulation of stress-activated mitogen-activated protein
17 kinase cascade, regulation of cell-substrate adhesion, and apoptotic processes (Figure 7G).

18

19 **DISCUSSION**

20 Our results suggest that MSCs can be safely and feasibly injected into the myocardium during
21 cardiac surgery for HLHS patients. Injection of allogeneic MSCs did not lead to apparent adverse
22 effects for up to 1 year, thus fulfilling the trial objectives. In addition, detailed CMR phenotyping
23 was undertaken to provide hypothesis generating data for larger trials aimed at further delineating

1 the effects of Lomecel-B on systemic RV performance. These studies provide key findings
2 suggesting that Lomecel-B may improve tricuspid valve function and RV global longitudinal
3 strain, possible evidence of improved ability to withstand the increased loads imposed by placing
4 the RV in the systemic position. Additionally, RNAs were identified in the serum specific
5 exosomes which provide a liquid biopsy that may be clinically useful in the development of this
6 approach, and may offer mechanistic insights into potential MSC effects that could contribute to
7 positive remodeling of the myocardium in HLHS patients.

8 MSCs are particularly attractive for pediatric applications because they can be reproducibly
9 isolated and expanded from donor bone marrow (34, 35). These cells have immunosuppressive
10 and pro-vascular properties and are effective as an allogeneic cell type as seen in previous adult
11 clinical trials (36-40), making them strong therapeutic candidates.

12 This trial enrolled patients with normal RVEF at baseline. Consistent with previous natural
13 history studies, RVEF drops following the stage II BDCPA due to loading condition alterations,
14 but remains in the normal range (41). It is estimated that ~10% of children develop frank RV failure
15 and require transplantation or die, with less than half of the children having transplant free survival
16 to 15 years of age (42). Accordingly, the initial ELPIS results are consistent with the salutary
17 effects of MSCs reported in preclinical studies, and are similar to the results of a variety of non-
18 cardiac stem cells or progenitor cells used previously in single-ventricle patients (20-22, 25). At
19 the 3-year follow-up of a phase II clinical trial, autologous intracoronary injection of cardiosphere-
20 derived cells was a safe therapy and improved RVEF in single-ventricle patients with severe RV
21 dysfunction at either their second or third palliative surgeries; however, the small, mixed study
22 population of different staged single-ventricle patients limited the ability to draw definitive
23 conclusions (20). Another phase I clinical trial demonstrated the safety of intramyocardial

1 injections of autologous umbilical cord-derived mononuclear cells in HLHS patients, but no
2 improvement of favorable RV remodeling was reported (24). Our results take advantage of an
3 allogeneic cell type with the additional benefits of using a potentially “off-the-shelf”, non-time
4 constrained product which can be frozen and used with repeat dosing for optimal efficacy.

5 We elected to deliver MSCs at the second staged operation to allow for stabilization of the
6 single-ventricle physiology in HLHS patients at a time when the mortality rate is lower compared
7 to the period between the first and second operations. There was no mortality in this small
8 population of treated HLHS patients, with a 100% one-year transplant-free survival rate. In
9 addition, our results demonstrate a non-statistical trend toward a reduction in RVEF from baseline
10 to 6- and 12-months post-treatment. Indeed, the observed trend is consistent with previous
11 published data reporting a decrease in RVEF from $58.3\pm 9.1\%$ at stage I of HLHS palliation to
12 $53.4\pm 6.6\%$ at stage II in a larger population of HLHS patients (43), a trend attributable to the
13 changes in loading conditions imposed by the stage II operation. Notably, global longitudinal
14 strain (GLS), a load independent marker of myocardial contractility, remained unchanged
15 throughout the follow up period compared to baseline. This is a promising observation since a
16 lower GLS is associated with death and heart transplantation in HLHS patients (44). A significant
17 reduction in CMR-derived tricuspid regurgitant fraction was observed at 6- and 12-months follow-
18 up. We also observed a trend toward decreasing BNP levels in the year following BDCPA. BNP
19 has been well demonstrated as a marker of cardiac dysfunction in patients with single-ventricle
20 physiology (45, 46), so this trend may suggest a progression toward improved cardiac function.

21 To gain molecular correlates of the observations, we measured RNA content of circulating
22 exosomes in a sub-group of patients, and used computational modeling not only to determine
23 whether 6-to-12 month functional changes can be predicted from early biomarkers, but also to

1 understand potential underlying mechanisms. Interestingly, samples taken a short time after cell
2 delivery (within a week) were able to model long-term functional changes: we constructed a
3 multivariate regression model and identified clusters of co-expressed genes correlated to
4 outcomes. While some computational tools can overfit data and force relationships, we used both
5 guided and unsupervised learning methods to explore these data and identified exosomal RNAs
6 deemed ‘important’ in both analyses. To our understanding, this is the first report of isolating cell
7 therapy-derived exosomes from treated children and of using the data to determine important early
8 biomarkers. We previously published this methodology using human cells in a rat model, and now
9 have extended it to human clinical trials (47). The ability to make predictions early in the
10 therapeutic timeline could allow clinicians to noninvasively monitor potential improvements and,
11 perhaps, even inform ongoing medical treatments. As we are presently conducting a phase II
12 randomized trial of this approach in HLHS, the ability to make a priori predictions could be quite
13 powerful and allow better model refinement and validation.

14 There are several caveats to our computational approach, including a small sample size
15 (n=6) due to the nature of the phase I trial, and the model merely predicts potential mechanisms,
16 and requires additional validation. These mechanisms may not be true functional mechanisms but
17 may instead be function improvement biomarkers. Future studies will need to confirm whether
18 these signals have functional effects markers of cardiac function.

19 ELPIS limitations include a small sample size and the absence of placebo-treated patients.
20 These are common to many phase I trials, which result from the novel nature of the treatment and
21 difficulty with masking because of the study intervention and design. We emphasize that ELPIS
22 was designed to investigate the intramyocardial MSC infusion safety and feasibility in HLHS
23 patients, and not the efficacy. All efficacy data are hypothesis generating intended to inform the

1 design of larger controlled studies. Furthermore, the importance of physiological changes created
2 by the surgical connection of the superior vena cava to the pulmonary artery on the RV function
3 is unclear because of limited previous serial CMR studies in HLHS patients.

4 In conclusion, the ELPIS I results suggest that allogeneic MSCs intramyocardial infusion
5 in HLHS patients is feasible, safe, and may have promising effects on the RV through 1-year after
6 treatment. Since ELPIS is the first study of MSCs in HLHS infants, the results are important for
7 advancing this new form of cell therapy for all ages and congenital heart conditions. The data from
8 our study warrant further, appropriately powered phase II studies which are currently underway.

1 **PERSPECTIVES**

2

3 **COMPETENCEY IN PATIENT CARE AND PROCEDURAL OUTCOME:** The ELPIS Phase I

4 study demonstrates the feasibility and safety of administrating allogenic MSCs to HLHS babies at

5 the time of the second Glenn operation. The study also suggests that exosomes specific to the

6 transplanted MSCs can be detected in the serum of treated babies which provides a liquid biopsy

7 for possible mechanistic pathways of myocardial remodeling.

8 **TRANSLATIONAL OUTLOOK:** Randomized studies are needed to verify the efficacy of the

9 allogeneic MSCs in HLHS babies.

1 REFERENCES

- 2 1. Gutgesell HP, Massaro TA. Management of hypoplastic left heart syndrome in a
3 consortium of university hospitals. *Am J Cardiol.* 1995;76(11):809-11.
- 4 2. Gordon BM, Rodriguez S, Lee M, Chang RK. Decreasing number of deaths of infants with
5 hypoplastic left heart syndrome. *J Pediatr.* 2008;153(3):354-8.
- 6 3. Reller MD, Strickland MJ, Riehle-Colarusso T, Mahle WT, Correa A. Prevalence of
7 congenital heart defects in metropolitan Atlanta, 1998-2005. *J Pediatr.* 2008;153(6):807-13.
- 8 4. Hoffman JI, Kaplan S. The incidence of congenital heart disease. *J Am Coll Cardiol.*
9 2002;39(12):1890-900.
- 10 5. Fruitman DS. Hypoplastic left heart syndrome: Prognosis and management options.
11 *Paediatr Child Health.* 2000;5(4):219-25.
- 12 6. Yabrodi M, Mastropietro CW. Hypoplastic left heart syndrome: from comfort care to long-
13 term survival. *Pediatr Res.* 2017;81(1-2):142-9.
- 14 7. McGuirk SP, Griselli M, Stumper OF, Rumball EM, Miller P, Dhillon R, et al. Staged
15 surgical management of hypoplastic left heart syndrome: a single institution 12 year experience.
16 *Heart.* 2006;92(3):364-70.
- 17 8. Feinstein JA, Benson DW, Dubin AM, Cohen MS, Maxey DM, Mahle WT, et al.
18 Hypoplastic left heart syndrome: current considerations and expectations. *J Am Coll Cardiol.*
19 2012;59(1 Suppl):S1-42.
- 20 9. Best KE, Miller N, Draper E, Tucker D, Luyt K, Rankin J. The Improved Prognosis of
21 Hypoplastic Left Heart: A Population-Based Register Study of 343 Cases in England and Wales.
22 *Frontiers in Pediatrics.* 2021;9.

- 1 10. Everitt MD, Boyle GJ, Schechtman KB, Zheng J, Bullock EA, Kaza AK, et al. Early
2 survival after heart transplant in young infants is lowest after failed single-ventricle palliation: a
3 multi-institutional study. *J Heart Lung Transplant*. 2012;31(5):509-16.
- 4 11. Williams AR, Trachtenberg B, Velazquez DL, McNiece I, Altman P, Rouy D, et al.
5 Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery
6 and reverse remodeling. *Circ Res*. 2011;108(7):792-6.
- 7 12. Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY,
8 et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells
9 delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON
10 randomized trial. *Jama*. 2012;308(22):2369-79.
- 11 13. Malliaras K, Makkar RR, Smith RR, Cheng K, Wu E, Bonow RO, et al. Intracoronary
12 cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the
13 final 1-year results of the CADUCEUS trial (CARDiosphere-Derived aUtologous stem CELls to
14 reverse ventricUlar dySfunction). *J Am Coll Cardiol*. 2014;63(2):110-22.
- 15 14. Gunasekaran M, Mishra R, Saha P, Morales D, Cheng WC, Jayaraman AR, et al.
16 Comparative efficacy and mechanism of action of cardiac progenitor cells after cardiac injury.
17 *iScience*. 2022;25(8):104656.
- 18 15. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, et al. A randomized,
19 double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal
20 stem cells (prochymal) after acute myocardial infarction. *J Am Coll Cardiol*. 2009;54(24):2277-
21 86.
- 22 16. Nguyen PK, Rhee JW, Wu JC. Adult Stem Cell Therapy and Heart Failure, 2000 to 2016:
23 A Systematic Review. *JAMA Cardiol*. 2016;1(7):831-41.

- 1 17. Banerjee MN, Bolli R, Hare JM. Clinical Studies of Cell Therapy in Cardiovascular
2 Medicine: Recent Developments and Future Directions. *Circ Res.* 2018;123(2):266-87.
- 3 18. Wehman B, Sharma S, Pietris N, Mishra R, Siddiqui OT, Bigham G, et al. Mesenchymal
4 stem cells preserve neonatal right ventricular function in a porcine model of pressure overload.
5 *Am J Physiol Heart Circ Physiol.* 2016;310(11):H1816-26.
- 6 19. Kanelidis AJ, Premer C, Lopez J, Balkan W, Hare JM. Route of Delivery Modulates the
7 Efficacy of Mesenchymal Stem Cell Therapy for Myocardial Infarction: A Meta-Analysis of
8 Preclinical Studies and Clinical Trials. *Circ Res.* 2017;120(7):1139-50.
- 9 20. Tarui S, Ishigami S, Ousaka D, Kasahara S, Ohtsuki S, Sano S, et al. Transcoronary
10 infusion of cardiac progenitor cells in hypoplastic left heart syndrome: Three-year follow-up of
11 the Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single-Ventricle
12 Physiology (TICAP) trial. *The Journal of thoracic and cardiovascular surgery.* 2015;150(5):1198-
13 207, 208 e1-2.
- 14 21. Ishigami S, Ohtsuki S, Eitoku T, Ousaka D, Kondo M, Kurita Y, et al. Intracoronary
15 Cardiac Progenitor Cells in Single Ventricle Physiology: The PERSEUS (Cardiac Progenitor Cell
16 Infusion to Treat Univentricular Heart Disease) Randomized Phase 2 Trial. *Circ Res.*
17 2017;120(7):1162-73.
- 18 22. Sano T, Ousaka D, Goto T, Ishigami S, Hirai K, Kasahara S, et al. Impact of Cardiac
19 Progenitor Cells on Heart Failure and Survival in Single Ventricle Congenital Heart Disease. *Circ*
20 *Res.* 2018;122(7):994-1005.
- 21 23. Vincenti M, O'Leary PW, Qureshi MY, Seisler DK, Burkhart HM, Cetta F, et al. Clinical
22 Impact of Autologous Cell Therapy on Hypoplastic Left Heart Syndrome After Bidirectional

- 1 Cavopulmonary Anastomosis. *Seminars in thoracic and cardiovascular surgery*. 2021;33(3):791-
- 2 801.
- 3 24. Burkhart HM, Qureshi MY, Rossano JW, Cantero Peral S, O'Leary PW, Hathcock M, et
- 4 al. Autologous stem cell therapy for hypoplastic left heart syndrome: Safety and feasibility of
- 5 intraoperative intramyocardial injections. *The Journal of thoracic and cardiovascular surgery*.
- 6 2019;158(6):1614-23.
- 7 25. Ishigami S, Ohtsuki S, Tarui S, Ousaka D, Eitoku T, Kondo M, et al. Intracoronary
- 8 autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: the
- 9 TICAP prospective phase 1 controlled trial. *Circ Res*. 2015;116(4):653-64.
- 10 26. Hare JM, DiFede DL, Rieger AC, Florea V, Landin AM, El-Khorazaty J, et al. Randomized
- 11 Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated
- 12 Cardiomyopathy: POSEIDON-DCM Trial. *J Am Coll Cardiol*. 2017;69(5):526-37.
- 13 27. Kaushal S, Wehman B, Pietris N, Naughton C, Bentzen SM, Bigham G, et al. Study design
- 14 and rationale for ELPIS: A phase I/IIb randomized pilot study of allogeneic human mesenchymal
- 15 stem cell injection in patients with hypoplastic left heart syndrome. *Am Heart J*. 2017;192:48-56.
- 16 28. Karantalis V, DiFede DL, Gerstenblith G, Pham S, Symes J, Zambrano JP, et al.
- 17 Autologous mesenchymal stem cells produce concordant improvements in regional function,
- 18 tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery
- 19 bypass grafting: The Prospective Randomized Study of Mesenchymal Stem Cell Therapy in
- 20 Patients Undergoing Cardiac Surgery (PROMETHEUS) trial. *Circ Res*. 2014;114(8):1302-10.
- 21 29. Carvalho BS, Irizarry RA. A framework for oligonucleotide microarray preprocessing.
- 22 *Bioinformatics*. 2010;26(19):2363-7.

- 1 30. MacDonald JW. (2016). *pd.clariom.s.human: Platform Design Info for Affymetrix*
2 *Clariom_S_Human* .
- 3 31. MacDonald JW. (2017). *clariomshumantranscriptcluster.db: Affymetrix clariomshuman*
4 *annotation data (chip clariomshumantranscriptcluster)*.
- 5 32. Haunsberger S. (2018). *miRBaseVersions.db: Collection of mature miRNA names of 22*
6 *different miRBase release versions*.
- 7 33. Carvalho B. (2015). *pd.mirna.4.0: Platform Design Info for Affymetrix miRNA-4_0*.
- 8 34. Pittenger MF, Discher DE, Peault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal
9 stem cell perspective: cell biology to clinical progress. *NPJ Regen Med*. 2019;4:22.
- 10 35. Andrzejewska A, Lukomska B, Janowski M. Concise Review: Mesenchymal Stem Cells:
11 From Roots to Boost. *Stem Cells*. 2019;37(7):855-64.
- 12 36. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions
13 between human mesenchymal stem cells and natural killer cells. *Stem Cells*. 2006;24(1):74-85.
- 14 37. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, et al.
15 Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival
16 in vivo. *Exp Hematol*. 2002;30(1):42-8.
- 17 38. Di Nicola M, Carlo-Stella C, Magni M, Milanese M, Longoni PD, Matteucci P, et al.
18 Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or
19 nonspecific mitogenic stimuli. *Blood*. 2002;99(10):3838-43.
- 20 39. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, et al. Human mesenchymal stem
21 cells inhibit differentiation and function of monocyte-derived dendritic cells. *Blood*.
22 2005;105(10):4120-6.

- 1 40. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O. HLA expression and
2 immunologic properties of differentiated and undifferentiated mesenchymal stem cells. *Exp*
3 *Hematol.* 2003;31(10):890-6.
- 4 41. Vincenti M, Qureshi MY, Niaz T, Seisler DK, Nelson TJ, Cetta F. Loss of Ventricular
5 Function After Bidirectional Cavopulmonary Connection: Who Is at Risk? *Pediatric cardiology.*
6 2020;41(8):1714-24.
- 7 42. Carrillo SA, Texter KM, Phelps C, Tan Y, McConnell PI, Galantowicz M. Tricuspid Valve
8 and Right Ventricular Function Throughout the Hybrid Palliation Strategy for Hypoplastic Left
9 Heart Syndrome and Variants. *World journal for pediatric & congenital heart surgery.*
10 2021;12(1):9-16.
- 11 43. Wong J, Lamata P, Rathod RH, Bertaud S, Dedieu N, Bellsham-Revell H, et al. Right
12 ventricular morphology and function following stage I palliation with a modified Blalock-Taussig
13 shunt versus a right ventricle-to-pulmonary artery conduit. *Eur J Cardiothorac Surg.*
14 2017;51(1):50-7.
- 15 44. Borrelli N, Di Salvo G, Sabatino J, Ibrahim A, Avesani M, Sirico D, et al. Serial changes
16 in longitudinal strain are associated with outcome in children with hypoplastic left heart syndrome.
17 *Int J Cardiol.* 2020;317:56-62.
- 18 45. Lowenthal A, Camacho BV, Lowenthal S, Natal-Hernandez L, Liszewski W, Hills NK, et
19 al. Usefulness of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide as
20 biomarkers for heart failure in young children with single ventricle congenital heart disease. *Am J*
21 *Cardiol.* 2012;109(6):866-72.

- 1 46. Shah A, Feraco AM, Harmon C, Tacy T, Fineman JR, Bernstein HS. Usefulness of various
2 plasma biomarkers for diagnosis of heart failure in children with single ventricle physiology. *Am*
3 *J Cardiol.* 2009;104(9):1280-4.
- 4 47. Saha P, Sharma S, Korutla L, Datla SR, Shoja-Taheri F, Mishra R, et al. Circulating
5 exosomes derived from transplanted progenitor cells aid the functional recovery of ischemic
6 myocardium. *Sci Transl Med.* 2019;11(493).

1 **Figure Titles and Captions**

2

3 **Figure 1** Study timeline and study flow, phase I of the ELPIS study.

4 **A**, Study timeline. **B**, Study flow. Patients who met the eligibility criteria underwent
5 BDCPA and intramyocardial injections, then were followed up with CMR at 6 and 12
6 months.

7 **Figure 2** Cardiac function at baseline, 6 months follow-up, and 12-month follow-up in

8 Lomecel-B treated patients (n=10). **A**, Right ventricular ejection fraction did not
9 change over the follow-up period compared to baseline. **B**, Right ventricle stroke
10 volume index did not change over the follow-up period compared to baseline. **C**,
11 Right ventricle diastolic diameter did not change over the follow-up period compared
12 to baseline. **D**, Right ventricle systolic diameter did not change over the follow-up
13 period compared to baseline. **E**, Global longitudinal strain did not change over the
14 follow-up period compared to baseline.

15 **Figure 3** Subjective tricuspid regurgitation at baseline, 6-month, and 12-month follow-up.

16 **A**, Subjective regurgitation was quantified as severe (3), moderate (2), or mild (1). **B**,
17 Tricuspid regurgitant fraction was measured. Reported as mean +/- standard
18 deviation. * indicates $p < 0.05$.

19 **Figure 4** Baseline and follow up data monitoring patients throughout ELPIS phase I trial

20 Lomecel-B treated patients. **A-B**, Serum BNP increased following day two post-
21 treatment but decreased following week twenty-four post-treatment. No changes were
22 statistically significant. Error bars indicate standard deviation. **C**, Somatic growth of
23 patients at baseline and at follow-up. Weight for age z-score increased from baseline

1 to 6 months. Weight for age z-score did not differ between baseline and 6 or 12
2 months. **D**, Length for age z-score increased from baseline to 6 months. The length
3 for age z-score significantly decreased from 6-month to 12-months ($p = 0.0136$) **E**,
4 HLA class I reactions significantly decreased from baseline to 26 weeks post-
5 treatment. **F**, HLA class II reactions showed a trend towards decreasing after
6 treatment, but this did not reach statistical significance. Only patients with HLA data
7 at baseline and 26 weeks are represented ($n=8$). * indicates $p < 0.05$. BNP, brain
8 natriuretic peptide. .

9 **Figure 5** Unsupervised analysis of MSC-derived exosome RNA.

10 **A**, Plasma exosomes from days 2 and 7 were assessed for miRNA and total RNA
11 content with microarray. RNA expression was related to CMR 6 months-to-1 year fold
12 change values. **B**, Volcano plot of RNA expression fold change from days 2 to 7. Few
13 miRNAs (circles) and RNAs (squares) upregulated in days 2 and 7 are highlighted in
14 orange and blue, respectively. Principal component analysis of days 2 and 7 miRNAs
15 (**C**), and RNAs (**D**). Merged dynamic clustering from weighted correlation network
16 analysis (WGCNA) detected 25 modules of highly correlated day 7 miRNAs (**E**) and
17 RNAs (**F**). Module correlation to CMR outcomes (6 months-to-1 year fold change) are
18 depicted in heatmaps (red = high, positive correlation). Modules significantly
19 correlated to an CMR outcome ($p < 0.1$) are marked. **G**, Enriched gene ontology (GO)
20 parent terms of WGCNA RNA modules negatively correlated to TR RF (M1 and M5)
21 and gene targets of miRNA modules positively correlated to TR RF (M12, M20, M25).
22 **H**, A network of experimentally validated gene targets of miRNAs positively correlated
23 to TR RF (M12, M20, M25). Enriched terms are colored by cluster (Metascape).

1 Figure 6 Representative western blots **A**, donor stem cell exosomes and **B**, tissue
2 positive controls. POD, post-operative day.

3 Figure 7 Partial least squares regression (PLSR) modeling of day 7 exosome RNA and
4 identification of RNA signals related to TR RF.

5 A two-component model was trained using the top 200 RNA variables of importance
6 for the model projection (VIPs): $R^2(\text{RNA}) = 0.927$, $R^2(\text{CMR Outcomes}) = 0.865$. **A**,
7 Total number of RNAs in the model was reduced to 200 from the initial set of 16,351.
8 A higher proportion of the VIP RNAs are miRNAs. **B**, Scores plot of components 1
9 and 2 from the PLSR model trained with day 7 top 200 VIP RNAs. Components 1 and
10 2 explain 80% and 13% of the the variance, respectively. **C**, Loadings plots of
11 components 1 and 2 from the PLSR model show the VIP RNAs covarying with CMR
12 outcomes. **D**, PLSR model predictions of CMR outcomes correlated with overserved
13 measurements. RNAs related to TR RF were determined from WGCNA and PLSR
14 analyses. **E**, Venn diagram of WGCNA modules significantly correlated to TR RF
15 ($p < 0.001$, miRNA M12, M20, M25 and RNA M1, M5) and PLSR 200 VIP RNAs. 54
16 TR RF-related RNAs identified from the intersection. **F**, Top 10 positive and negative
17 weighted coefficients from TR RF-related RNAs were determined with PLSR. **G**,
18 Pathway analysis of 54 TR RF-related RNAs (Metascape).
19

1 **Table 1. Baseline Demographics**

Characteristic ^a	Lomecel-B (N=10)	Allo-MSCs (N=4)	All (N=14)
Age at BDCPA operation (months)	4.89±0.85	4.83±0.59	4.87±0.76
Male gender	7 (70.0)	1 (25.0)	8 (57.19)
Ethnicity			
Hispanic or Latino	0	2 (50.0)	2 (14.3)
Not Hispanic or Latino	10 (100.0)	2 (50.0)	12 (85.7)
Race			
White	7 (70.0)	0	7 (50.02)
Black/African American	3 (30.0)	2 (50.0)	5 (35.7)
Not collected	0	1 (25.0)	1 (7.1)
Other	0	1 (25.0)	1 (7.1)
Body Surface Area (m ²)	0.331±0.03	0.327±0.032	0.33±0.029
Length for Age Z-Score	-0.87±2.02	-1.350±0.719	-1.01±1.73
Weight for Age Z-Score	-1.09±1.31	-0.450±0.656	-0.91±1.17
Duration of Bypass (min)	113.1±17.44	101.0±11.14	109.6±16.69
Duration of Injection (min)	5.5±1.78	6.2±0.96	5.7±1.59
Hospital Length of Stay (days)	11.7±9.58	7.25±0.50	10.43±8.24
Norwood Shunt Type			
RV-PA (Sano)	10 (100)	4 (100)	14 (100)
RV Function by CMR			

RV Ejection Fraction (%)	62.62±5.99	67.97±11.02	64.15±7.69
RV End Systolic Volume Index (mL/m ² BSA ^{1.3})	49.7 1± 15.61	61.38±48.43	53.04±27.2
RV End Diastolic Volume Index (mL/m ² BSA ^{1.3})	133.59±36.14	170.25±85.19	144.06±53.62
RV Stroke Volume Index (mL/m ² BSA ^{1.3})	83.88±23.65	108.87±37.03	91.02±29
RV Mass Index (g/m ² BSA ^{1.3})	101.26±33.71	116.15±34.97	105.52±33.43
Tricuspid regurgitant fraction	0.45±0.19	0.51±0.20	0.48±0.18
RV systolic diameter (mm/m ² √BSA)	37.5±9.24	40.49±22.07	38.35±13.17
RV diastolic diameter (mm/m ² √BSA)	61.36±13.95	68.00±21.56	63.26±15.87
GLS (%)	-24.39±6.99	-21.29±6.65	-23.26±6.71
Sphericity Index	1.31±0.35	1.30±0.26	1.30±0.31

^aValues are n (%) or mean±SD unless otherwise noted

Table 2. Patient characteristics at the time of stage II procedure

Characteristic ^a	Lomecel-B (N=10)
Anatomic diagnosis HLHS	10 (100.0)
Morphology	
Mitral atresia and aortic atresia	6 (60)
Mitral stenosis and aortic atresia	3 (30)
Mitral atresia and aortic stenosis	0
Mitral stenosis and aortic stenosis	1 (10)
Partially restrictive atrial septal defect	1 (10)
Sinusoidal arteries	0
Aortic size before first palliation (mm)	1.70±0.46
Cardiac position levocardia	10 (100.0)
Associated anomaly	
Right aortic arch	0
Bilateral SVC	1 (10)
Previous cardiac surgical procedures	
Norwood operation	10 (100.0)
Age at Norwood (days)	4.3±1.25
Modified Blalock-Taussig shunt	0
Sano shunt	10 (100.0)

Cardiac arrest	0
ECMO	0
History of bilateral pulmonary artery banding	1 (20)
TAPVC	1 (10)
Damus-Kaye-Stansel anastomosis	3 (30)
History of catheter interventions	
Balloon atrial septostomy	1 (10)
APCA coil occlusion	1 (10)
Pulmonary artery angioplasty	0
Balloon of distal coarctation of aorta	2 (20)
Preoperative assessment	
Genetic syndrome	0 (0)
Extracardiac malformation	1 (10)
Mild tricuspid regurgitation	1 (10)
Oxygen saturation %	80.6±3.34
Aortic saturation % (n=9)	78.06±10.01
Mean BNP [range] (µg/mL)	759.1 [45.0 – 3190.0]
Mean pulmonary artery pressure (mmHg) (n=9)	13.56±2.55
Cardiac index (L/min/m ²) (n=9)	3.25±0.8
Coarctation of aorta (n = 7)	1 (10)
Medication profile	

Diuretics	7 (70)
Digoxin	10 (100)
Digitalis	0 (0)
ACE inhibitor or ARB	4 (40)
PDE5	0
Endothelin-1 receptor antagonist	0
Aspirin (Antiplatelet)	10 (100)
Beta-blocker	2 (20)
Antiarrhythmic agent	0 (0)
Anti-reflux agent	8 (80)

^aValues are n (%) or mean±SD unless otherwise noted

ACE, Angiotensin-converting enzyme; APCA, aortopulmonary collateral arteries; ARB, angiotensin II receptor blocker; BNP, brain natriuretic peptide; ECMO, extracorporeal membrane oxygenation; HLHS, hypoplastic left heart syndrome; PDE5, phosphodiesterase type 5; SVC, superior vena cava; TAPVC, total anomalous pulmonary venous connection

Table 3. Operative characteristics of study population during bidirectional cavopulmonary anastomosis and stem cell injection

Operative Variable ^a	Lomecel-B(N=10)
Concomitant procedures	
Atrial septectomy ^a	4 (40)
Pulmonary artery patch augmentation ^a	4 (40)
Aortic cross clamp	
Number of patients	0
Average time (min)	0
Deep hypothermic circulatory arrest	
Number of patients	0
Average time (min)	0
Average MSC trial injection time (min)	5.5±1.78
Average volume of MSC injected (µL)	600.0±0.0
Average number of MSC injections	8.0±0.0
Average length of hospitalization (days)	11.7±9.58 ^b

^aValues are N (%) or mean±SD unless otherwise noted

^bLength of stay consistent with 2016-2020 STS Benchmark data (unpublished) which shows median postoperative length of stay for Glenn/hemi-Fontan procedures is 17.8 days.

MSC, medicinal signaling cell

Table 4. Incidence of major adverse cardiac events and co-morbidities.

	Number of Incidences
	Lomecel-B (N=10)
Major Adverse Cardiac Events ^a	
Sustained/symptomatic ventricular tachycardia requiring intervention with inotropic support	0
Aggravation of heart failure	0
Myocardial infarction	0
Unplanned cardiovascular operation for cardiac tamponade	0
Death	0
Co-morbidities	
Cardiovascular morbidity ^b	1
Need for transplantation	0
Re-hospitalizations	10 (5 patients)
Cardiovascular mortality	0
All-cause morbidity	0

^aEvaluated through 1 year post-treatment

^bThe one cardiovascular morbidity was an ascending aorta obstruction which required angioplasty




Figure 1. Study timeline and study flow, phase I of the ELPIS study. **A**, Study timeline. **B**, Study flow. Patients who met the eligibility criteria underwent BDCPA and intramyocardial injections, then were followed up with CMR at 6 and 12 months.




Figure 2. Cardiac function at baseline, 6 months follow-up, and 12-month follow-up in Lomecel-B treated patients (n=10). **A**, Right ventricular ejection fraction did not change over the follow-up period compared to baseline. **B**, Right ventricle stroke volume index did not change over the follow-up period compared to baseline. **C**, Right ventricle diastolic diameter did not change over the follow-up period compared to baseline. **D**, Right ventricle systolic diameter did not change over the follow-up period compared to baseline. **E**, Global longitudinal strain did not change over the follow-up period compared to baseline.




Figure 3. Subjective tricuspid regurgitation at baseline, 6-months, and 12-months follow-up. **A**, Subjective regurgitation was quantified as severe (3), moderate (2), or mild (1). **B**, Tricuspid regurgitant fraction was measured. Reported as mean +/- standard deviation. * indicates $p < 0.05$.




Figure 4. Baseline and follow up data monitoring patients throughout ELPIS phase I trial Lomecel-B treated patients. **A-B**, Serum BNP increased following day two post-treatment but decreased following week twenty-four post-treatment. No changes were statistically significant. Error bars indicate standard deviation. **C**, Somatic growth of patients at baseline and at follow-up. Weight for age z-score increased from baseline to 6 months. Weight for age z-score did not differ between baseline and 6 or 12 months. **D**, Length for age z-score increased from baseline to 6 months. The length for age z-score significantly decreased from 6-month to 12-months ($p = 0.0136$) **E**, HLA class I reactions significantly decreased from baseline to 26 weeks post-treatment. **F**, HLA class II reactions showed a trend towards decreasing after treatment, but this did not reach statistical significance. Only patients with HLA data at baseline and 26 weeks are represented ($n=8$). * indicates $p < 0.05$. BNP, brain natriuretic peptide.




Figure 5. Unsupervised analysis of MSC-derived exosome RNA. **A**, Plasma exosomes from days 2 and 7 were assessed for miRNA and total RNA content with microarray. RNA expression was related to CMR 6 months-to-1 year fold change values. **B**, Volcano plot of RNA expression fold change from days 2 to 7. Few miRNAs (circles) and RNAs (squares) upregulated in days 2 and 7 are highlighted in orange and blue, respectively. Principal component analysis of days 2 and 7 miRNAs (**C**), and RNAs (**D**). Merged dynamic clustering from weighted correlation network analysis (WGCNA) detected 25 modules of highly correlated day 7 miRNAs (**E**) and RNAs (**F**). Module correlation to CMR outcomes (6 months-to-1 year fold change) are depicted in heatmaps (red = high, positive correlation). Modules significantly correlated to an CMR outcome ($p < 0.1$) are marked. **G**, Enriched gene ontology (GO) parent terms of WGCNA RNA modules negatively correlated to TR RF (M1 and M5) and gene targets of miRNA modules positively correlated to TR RF (M12, M20, M25). **H**, A network of experimentally validated gene targets of miRNAs positively correlated to TR RF (M12, M20, M25). Enriched terms are colored by cluster (Metascape).




Figure 6. Representative western blots **A**, donor stem cell exosomes and **B**, tissue positive controls. POD, post-operative day.




Figure 7. Partial least squares regression (PLSR) modeling of day 7 exosome RNA and identification of RNA signals related to TR RF. A two-component model was trained using the top 200 RNA variables of importance for the model projection (VIPs): $R^2(\text{RNA}) = 0.927$, $R^2(\text{CMR Outcomes}) = 0.865$. **A**, Total number of RNAs in the model was reduced to 200 from the initial set of 16,351. A higher proportion of the VIP RNAs are miRNAs. **B**, Scores plot of components 1 and 2 from the PLSR model trained with day 7 top 200 VIP RNAs. Components 1 and 2 explain 80% and 13% of the the variance, respectively. **C**, Loadings plots of components 1 and 2 from the PLSR model show the VIP RNAs covarying with CMR outcomes. **D**, PLSR model predictions of CMR outcomes correlated with overserved measurements. RNAs related to TR RF were determined from WGCNA and PLSR analyses. **E**, Venn diagram of WGCNA modules significantly correlated to TR RF ($p < 0.001$, miRNA M12, M20, M25 and RNA M1, M5) and PLSR 200 VIP RNAs. 54 TR RF-related RNAs identified from the intersection. **F**, Top 10 positive and negative weighted coefficients from TR RF-related RNAs were determined with PLSR. **G**, Pathway analysis of 54 TR RF-related RNAs (Metascape).

Supplemental Table 1. ELPIS phase I clinical outcomes. (Lomecel-B)

Measure	Baseline (n=10)	6-month (n=9)	12-month (n=8)	6-month Change from Baseline	12-month Change from Baseline
BSA (m ²)	0.331±0.03	0.432±0.03	0.478±0.034	0.105±0.03*	0.144±0.037†
Length for Age Z-Score	-0.9±2.0	0.2±1.3	-1.2±0.8	1.24±1.64	-0.40±1.83‡
Weight for Age Z-Score	-1.1±1.3	-0.3±1.0	-0.6±0.8	0.83±1.28	0.23±1.13
RV Ejection Fraction (%)	62.62±5.99	53.69±9.56	52.31±5.63	-8.89±10.93	-10.88±10.7
RV End Systolic Volume Index (mL/m ² BSA ^{1.3})	49.71±15.61	69.85±19.87	63.03±13.39	18.69±24.2	15.3±19.42
RV End Diastolic Volume Index (mL/m ² BSA ^{1.3})	133.59±36.14	152.07±32.09	133.44±31.42	14.65±46.73	2.55±48.04
RV Stroke Volume Index (mL/m ² BSA ^{1.3})	83.88±23.65	82.22±25.25	70.41±20.5	-4.05±33.35	-12.75±34.8
RV Mass Index (g/m ² BSA ^{1.3})	101.26±33.71	110.82±29.63	97.88±24.22	7.69±30.22	2.23±33.48
TR fraction	0.45±0.19	0.32±0.06	0.06±0.09	-0.09±0.33	-0.52±0.07
RV systolic diameter (mm/m ² √BSA)	37.5±9.24	45.76±11.79	41.54±8.59	7.75±8.89	3.84±7.98
RV diastolic diameter (mm/m ² √BSA)	61.36±13.95	64.48±11.03	62.61±9.44	2.17±8.44	-0.65±8.41
GLS (%)	-24.39±6.99	-20.55±3.05	-23.88±4.6	2.6±8.25	0.06±10.76
Sphericity Index	1.31±0.35	1.21±0.26	1.22±0.21	-0.1±0.17	-0.02±0.19

BSA: body surface area; GLS: global longitudinal strain; RV: right ventricle

*p<0.0001 vs baseline, and †p<0.01, ‡p<0.05 vs 6-months using One-Way ANOVA with Mixed-Effects Model for multiple comparisons and Bonferroni correction.

Supplemental Table 2. ELPIS phase I clinical outcomes. (Allo-MSCs)

Measure	Baseline (n=4)	6-month (n=4)	12-month (n=4)	6-month Change from Baseline	12-month Change from Baseline
BSA (m ²)	0.327±0.032	0.415±0.038	0.458±0.040	0.088±0.023 *	0.131±0.028†
Length for Age Z-Score	-1.350±0.719	-1.400±1.745	-0.450±1.462	-0.050±1.173	0.900±1.042
Weight for Age Z-Score	-0.450±0.656	0.125±0.263	-0.600±1.030	0.575±0.629	-0.150±0.714
RV Ejection Fraction (%)	67.97±11.02	58.36±10.81	56.46±16.55	-9.77±3.46	-11.52 ± 9.09
RV End Systolic Volume Index (mL/m ² BSA ^{1.3})	61.38±48.43	91.19±63.78	89.95±77.72	26.65±5.60*	28.57±36.06
RV End Diastolic Volume Index (mL/m ² BSA ^{1.3})	170.25±85.19	204.53±100.14	184.38±81.51	30.75±20.68	14.13±40.91
RV Stroke Volume Index (mL/m ² BSA ^{1.3})	108.87±37.03	113.34±37.36	94.44±8.91	4.10±19.96	-14.44±38.23
RV Mass Index (g/m ² BSA ^{1.3})	116.15±34.97	133.54±39.34	105.40±45.95	7.94±4.12	-10.75±16.60
TR fraction ^a	0.51±0.20	0.36±0.37	0.32±0.20	-0.15±0.17	-0.19±0.14
RV systolic diameter (mm/m ² √BSA)	40.49±22.07	52.60±28.66	49.66±20.24	9.40±6.97	9.17±7.29
RV diastolic diameter (mm/m ² √BSA)	68.00±21.56	76.61±21.48	68.78±21.47	4.68±3.47	0.78±7.58
GLS (%)	-21.29±6.65	-20.91 ± 3.36	-24.30±3.75	-2.93±3.12	-3.01±2.90
Sphericity Index	1.30±0.26	1.05±0.21	1.38±0.32	-0.19±0.30	0.08±0.16

BSA: body surface area; GLS: global longitudinal strain; RV: right ventricle

*p<0.05, †p<0.01vs baseline using One-Way ANOVA with Mixed-Effects Model for multiple comparisons and Bonferroni correction.